Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash-to-Debt 0.28
TRNX's Cash-to-Debt is ranked lower than
85% of the 323 Companies
in the Global Medical Devices industry.

( Industry Median: 2.54 vs. TRNX: 0.28 )
Ranked among companies with meaningful Cash-to-Debt only.
TRNX' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.18  Med: 0.42 Max: 1.53
Current: 0.28
0.18
1.53
Equity-to-Asset 0.28
TRNX's Equity-to-Asset is ranked lower than
88% of the 300 Companies
in the Global Medical Devices industry.

( Industry Median: 0.65 vs. TRNX: 0.28 )
Ranked among companies with meaningful Equity-to-Asset only.
TRNX' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.27  Med: 0.7 Max: 0.79
Current: 0.28
0.27
0.79
Debt-to-Equity 1.27
TRNX's Debt-to-Equity is ranked lower than
92% of the 204 Companies
in the Global Medical Devices industry.

( Industry Median: 0.29 vs. TRNX: 1.27 )
Ranked among companies with meaningful Debt-to-Equity only.
TRNX' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.1  Med: 0.2 Max: 1.27
Current: 1.27
0.1
1.27
Piotroski F-Score: 5
Altman Z-Score: 0.60
Beneish M-Score: -3.18
WACC vs ROIC
6.48%
-5.81%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating Margin % -10.79
TRNX's Operating Margin % is ranked lower than
66% of the 303 Companies
in the Global Medical Devices industry.

( Industry Median: 3.45 vs. TRNX: -10.79 )
Ranked among companies with meaningful Operating Margin % only.
TRNX' s Operating Margin % Range Over the Past 10 Years
Min: -116.46  Med: -16.1 Max: -2.74
Current: -10.79
-116.46
-2.74
Net Margin % -36.04
TRNX's Net Margin % is ranked lower than
73% of the 303 Companies
in the Global Medical Devices industry.

( Industry Median: 1.77 vs. TRNX: -36.04 )
Ranked among companies with meaningful Net Margin % only.
TRNX' s Net Margin % Range Over the Past 10 Years
Min: -113.05  Med: -27.11 Max: -7.84
Current: -36.04
-113.05
-7.84
ROE % -35.76
TRNX's ROE % is ranked lower than
80% of the 295 Companies
in the Global Medical Devices industry.

( Industry Median: 2.13 vs. TRNX: -35.76 )
Ranked among companies with meaningful ROE % only.
TRNX' s ROE % Range Over the Past 10 Years
Min: -64.55  Med: -24.23 Max: -5.19
Current: -35.76
-64.55
-5.19
ROA % -11.01
TRNX's ROA % is ranked lower than
67% of the 324 Companies
in the Global Medical Devices industry.

( Industry Median: 0.49 vs. TRNX: -11.01 )
Ranked among companies with meaningful ROA % only.
TRNX' s ROA % Range Over the Past 10 Years
Min: -40.3  Med: -10.97 Max: -3.73
Current: -11.01
-40.3
-3.73
ROC (Joel Greenblatt) % -32.61
TRNX's ROC (Joel Greenblatt) % is ranked lower than
63% of the 321 Companies
in the Global Medical Devices industry.

( Industry Median: 6.15 vs. TRNX: -32.61 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
TRNX' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -197.56  Med: -35.23 Max: -18
Current: -32.61
-197.56
-18
3-Year Revenue Growth Rate 10.00
TRNX's 3-Year Revenue Growth Rate is ranked higher than
67% of the 239 Companies
in the Global Medical Devices industry.

( Industry Median: 5.30 vs. TRNX: 10.00 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
TRNX' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -14.9  Med: -4.3 Max: 10
Current: 10
-14.9
10
3-Year EBITDA Growth Rate -58.80
TRNX's 3-Year EBITDA Growth Rate is ranked lower than
96% of the 210 Companies
in the Global Medical Devices industry.

( Industry Median: 6.30 vs. TRNX: -58.80 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
TRNX' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -58.8  Med: -11.9 Max: 101.8
Current: -58.8
-58.8
101.8
3-Year EPS without NRI Growth Rate -35.00
TRNX's 3-Year EPS without NRI Growth Rate is ranked lower than
85% of the 206 Companies
in the Global Medical Devices industry.

( Industry Median: 2.90 vs. TRNX: -35.00 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
TRNX' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -38.1  Med: 20.2 Max: 89.2
Current: -35
-38.1
89.2
GuruFocus has detected 2 Warning Signs with Tornier NV $TRNX.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» TRNX's 30-Y Financials

Financials (Next Earnings Date: 2017-11-02 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

TRNX Guru Trades in

Q2 2015

TRNX Guru Trades in Q2 2015

Steven Cohen 36,000 sh (-81.09%)
» More
Q3 2015

TRNX Guru Trades in Q3 2015

Steven Cohen 415,700 sh (+1054.72%)
» More
Q4 2015

TRNX Guru Trades in Q4 2015

Steven Cohen Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with TRNX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Devices » Medical Devices    NAICS: 339113    SIC: 3842
Compare: » details
Traded in other countries:T98.Germany,
Headquarter Location:Netherlands
Wright Medical Group NV is a medical device company that manufactures & sells extremities and biologics products in USA & internationally. It offers joint implants & bone fusion & fixation devices for shoulder, elbow, wrist, and hand.

Wright Medical Group develops medical devices and products in five categories: lower extremities, upper extremities, biologics, large joints, and sport medicine, and other. Products for lower extremities include joint implants and bone fixation devices for the foot and ankle, whereas products for upper extremities include implants and devices for the shoulder, elbow, wrist, and hand. The biologics business sells products used to treat damaged or diseased bone, tendons, and soft tissues or to stimulate bone growth. The large joints business sells hip and knee replacement implants. The firm's sports medicine products are used to mechanically repair tissue injuries. Wright Medical Group generates the majority of its revenue in the United States.

Top Ranked Articles about Tornier NV

Wright Medical Group N.V. to Present at Baird 2017 Global Healthcare Conference
Keeley Funds Comments on Wright Medical Group Guru stock highlight
Wright Medical Group (NASDAQ:WMGI) is a global medical device company focused on extremities and biologics. The company had exceeded analysts’ estimates for the past four quarters and EBITDA margins have increased from -5.5% in 4Q15 to 11.7% in 4Q16, on its way towards their 20% margin target by 2019. Unfortunately, the company missed first quarter 2017 earnings as a planned salesforce expansion did not lead to increased sales as quickly as hoped. Underlying metrics remain strong and the company should recover as the year proceeds. In addition, a recent Financial Times article reported on speculation that a larger orthopedic company may be looking to acquire Wright. Given the consolidation in the orthopedic market and CEO Palmisano’s history of selling his prior companies, we would not be surprised if a strategic player recognizes Wright’s intrinsic value sooner than expected. Read more...
Wright Medical Group N.V. Highlights New Innovations at the American Orthopaedic Foot and Ankle Society (AOFAS) 2017 Annual Meeting
Wright Medical Group N.V. to Present at William Blair Growth Stock Conference
Wright Medical Group N.V. to Present at UBS Global Healthcare Conference
Keeley Funds Comments on Wright Medical Group Guru stock highlight
Wright Medical Group (NASDAQ:WMGI) is a global medical device company focused on extremities and biologics. The company completed a merger of equals with Tornier NV in late 2015 becoming the worldwide leader in providing surgical solutions for upper extremities (shoulder, elbow, wrist and hands), lower extremities (foot and ankle) and biologics (bone graft stimulators) - three of the fastest growing segments in orthopedics. Both companies had been investing heavily for growth resulting in low, short-term profitability, but under new CEO Robert Palmisano, the combined company has substantial scale opportunities and would be a beneficiary of the aging, but much more active baby boom generation. The company has exceeded analysts’ estimates for the past four quarters post the deal closing and EBITDA margins have increased from -5.5% in 4Q15 to 11.7% in 4Q16, on its way towards our 20% margin target by 2019. In addition, a recent Financial Times article reported on speculation that a larger orthopedic company may be looking to acquire Wright. Given the consolidation in the orthopedic market and CEO Palmisano’s history Read more...
Wright Medical Group N.V. to Host First Quarter 2017 Earnings Conference Call
Wright Medical Group N.V. to Present at Needham Healthcare Conference

Wednesday, April 5, 2017 at 2:20 p.m. Eastern Time 

AMSTERDAM, The Netherlands, March 24, 2017 (GLOBE NEWSWIRE) -- Wright Medical Group N.V. (NASDAQ:WMGI) announced today that it will present at the Needham Healthcare Conference on Wednesday, April 5, 2017, at the Westin NY Grand Central Hotel in New York, New York.  Lance Berry, chief financial officer, will present at 2:20 p.m. Eastern Time.  
A live audio webcast of the conference presentation, along with the accompanying presentation materials, will be available on Wright’s corporate website at www.wright.com, under the “Investor Relations” link.  The audio webcast and accompanying presentation materials will be archived on this site under the “Investor Presentations” link following the conference. Internet Posting of Information Wright routinely posts information that may be important to investors in the “Investor Relations” section of its website at www.wright.com.  The company encourages investors and potential investors to consult the Wright website regularly for important information about Wright. About Wright Medical Group N.V. Wright Medical Group N.V. is a global medical device company focused on extremities and biologics products.  The company is committed to delivering innovative, value-added solutions improving quality of life for patients worldwide and is a recognized leader of surgical solutions for the upper extremity (shoulder, elbow, wrist and hand), lower extremity (foot and ankle) and biologics markets, three of the fastest growing segments in orthopedics.  For more information about Wright, visit www.wright.com.
Investors & Media:

Julie D. Tracy
Sr. Vice President, Chief Communications Officer
Wright Medical Group N.V.
(901) 290-5817
[email protected]


Read more...
Keeley Asset Management Comments on Wright Medical Group Guru stock highlight
One of the Fund’s main drivers this quarter was Wright Medical Group (NASDAQ:WMGI), which gained nearly 40% and contributed 141 basis points in performance. The company provides surgical solutions for the foot and ankle market and its products include joint implants for hip and knee replacements. The company reported a strong second quarter and raised guidance, proving the benefit of the Tornier acquisition. Read more...

Ratios

vs
industry
vs
history
Forward PE Ratio 1428.57
TRNX's Forward PE Ratio is ranked lower than
99.99% of the 49 Companies
in the Global Medical Devices industry.

( Industry Median: 25.64 vs. TRNX: 1428.57 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PB Ratio 4.40
TRNX's PB Ratio is ranked lower than
64% of the 291 Companies
in the Global Medical Devices industry.

( Industry Median: 2.92 vs. TRNX: 4.40 )
Ranked among companies with meaningful PB Ratio only.
TRNX' s PB Ratio Range Over the Past 10 Years
Min: 1.47  Med: 2.16 Max: 4.95
Current: 4.4
1.47
4.95
PS Ratio 3.92
TRNX's PS Ratio is ranked lower than
60% of the 290 Companies
in the Global Medical Devices industry.

( Industry Median: 3.32 vs. TRNX: 3.92 )
Ranked among companies with meaningful PS Ratio only.
TRNX' s PS Ratio Range Over the Past 10 Years
Min: 2.22  Med: 3.52 Max: 5.13
Current: 3.92
2.22
5.13
Price-to-Operating-Cash-Flow 54.97
TRNX's Price-to-Operating-Cash-Flow is ranked lower than
95% of the 135 Companies
in the Global Medical Devices industry.

( Industry Median: 19.50 vs. TRNX: 54.97 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
TRNX' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 26.97  Med: 43.47 Max: 167.07
Current: 54.97
26.97
167.07
EV-to-EBIT -44.34
TRNX's EV-to-EBIT is ranked lower than
99.99% of the 177 Companies
in the Global Medical Devices industry.

( Industry Median: 24.67 vs. TRNX: -44.34 )
Ranked among companies with meaningful EV-to-EBIT only.
TRNX' s EV-to-EBIT Range Over the Past 10 Years
Min: -220.5  Med: -18.85 Max: -3.1
Current: -44.34
-220.5
-3.1
EV-to-EBITDA 352.49
TRNX's EV-to-EBITDA is ranked lower than
99.99% of the 183 Companies
in the Global Medical Devices industry.

( Industry Median: 17.99 vs. TRNX: 352.49 )
Ranked among companies with meaningful EV-to-EBITDA only.
TRNX' s EV-to-EBITDA Range Over the Past 10 Years
Min: -304.6  Med: -14.25 Max: 640.7
Current: 352.49
-304.6
640.7
EV-to-Revenue 4.78
TRNX's EV-to-Revenue is ranked lower than
62% of the 296 Companies
in the Global Medical Devices industry.

( Industry Median: 3.70 vs. TRNX: 4.78 )
Ranked among companies with meaningful EV-to-Revenue only.
TRNX' s EV-to-Revenue Range Over the Past 10 Years
Min: 2.3  Med: 4.2 Max: 7.2
Current: 4.78
2.3
7.2
Current Ratio 1.45
TRNX's Current Ratio is ranked lower than
87% of the 319 Companies
in the Global Medical Devices industry.

( Industry Median: 2.64 vs. TRNX: 1.45 )
Ranked among companies with meaningful Current Ratio only.
TRNX' s Current Ratio Range Over the Past 10 Years
Min: 0.95  Med: 2.56 Max: 3.29
Current: 1.45
0.95
3.29
Quick Ratio 1.12
TRNX's Quick Ratio is ranked lower than
84% of the 319 Companies
in the Global Medical Devices industry.

( Industry Median: 1.92 vs. TRNX: 1.12 )
Ranked among companies with meaningful Quick Ratio only.
TRNX' s Quick Ratio Range Over the Past 10 Years
Min: 0.8  Med: 1.53 Max: 1.99
Current: 1.12
0.8
1.99
Days Inventory 347.85
TRNX's Days Inventory is ranked lower than
91% of the 285 Companies
in the Global Medical Devices industry.

( Industry Median: 128.08 vs. TRNX: 347.85 )
Ranked among companies with meaningful Days Inventory only.
TRNX' s Days Inventory Range Over the Past 10 Years
Min: 342.93  Med: 428.02 Max: 530.83
Current: 347.85
342.93
530.83
Days Sales Outstanding 60.32
TRNX's Days Sales Outstanding is ranked higher than
58% of the 273 Companies
in the Global Medical Devices industry.

( Industry Median: 68.17 vs. TRNX: 60.32 )
Ranked among companies with meaningful Days Sales Outstanding only.
TRNX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 60.32  Med: 71.27 Max: 118.01
Current: 60.32
60.32
118.01
Days Payable 90.76
TRNX's Days Payable is ranked higher than
60% of the 258 Companies
in the Global Medical Devices industry.

( Industry Median: 54.45 vs. TRNX: 90.76 )
Ranked among companies with meaningful Days Payable only.
TRNX' s Days Payable Range Over the Past 10 Years
Min: 51.36  Med: 83.39 Max: 156.08
Current: 90.76
51.36
156.08

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -28.70
TRNX's 3-Year Average Share Buyback Ratio is ranked lower than
85% of the 226 Companies
in the Global Medical Devices industry.

( Industry Median: -4.10 vs. TRNX: -28.70 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
TRNX' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -35  Med: -20 Max: -7.6
Current: -28.7
-35
-7.6

Valuation & Return

vs
industry
vs
history
Price-to-Median-PS-Value 1.12
TRNX's Price-to-Median-PS-Value is ranked lower than
62% of the 275 Companies
in the Global Medical Devices industry.

( Industry Median: 1.01 vs. TRNX: 1.12 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
TRNX' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.69  Med: 1.02 Max: 1.34
Current: 1.12
0.69
1.34
Earnings Yield (Greenblatt) % -2.26
TRNX's Earnings Yield (Greenblatt) % is ranked lower than
61% of the 323 Companies
in the Global Medical Devices industry.

( Industry Median: 1.25 vs. TRNX: -2.26 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
TRNX' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -32.2  Med: -5.3 Max: -0.5
Current: -2.26
-32.2
-0.5

More Statistics

Short Percentage of Float6.00%
52-Week Range $20.25 - 28.53
Shares Outstanding (Mil)49.27

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}